Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
Shauna O'Brien Mar 16, 2015
In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.
The adjusted deal has been approved by the Boards of Directors of both companies.
Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.
|PRGFX||T. Rowe Price Growth Stock||1.33%|
|SEEGX||JPMorgan Large Cap Growth Select||0.68%|
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Subscribe to receive FREE updates, insigns, and more, straight to your inbox